Replimune Group Inc (REPL) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $7.69
• Market Cap: $677.10M
• EPS: $-3.44
• 52-Week High: $13.24
• 52-Week Low: $2.68

Market Sentiment

Replimune Group Inc currently has a Neutral sentiment score of 0.06.

About Replimune Group Inc

Replimune Group, Inc., headquartered in Woburn, Massachusetts, is at the forefront of biotechnology, specializing in the development of oncolytic immunotherapies aimed at revolutionizing cancer treatment. Utilizing its proprietary Immuno-Oncology platform, the company targets cancer cells with precision while enhancing the body's immune response against tumors. Replimune's advancing clinical programs demonstrate the potential effectiveness of its innovative therapies, establishing it as a key...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Replimune Group Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does REPL pay dividends?

Replimune Group Inc (REPL) does not currently pay a regular dividend.

What is REPL's market cap?

Replimune Group Inc (REPL) has a market capitalization of $677.10M with a current stock price of $7.69.